Former Pfizer Executive Subpoenaed by House Judiciary Committee | The American Spectator

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the release of COVID vaccine information. It is alleged that senior officials at Pfizer withheld positive trials concerning the COVID vaccine for political purposes, only releasing it after Joe Biden had been elected.

Dormitzer worked for GSK, a global pharmaceutical company, after his career with Pfizer. The committee discovered that Dormitzer allegedly admitted to Pfizer’s dishonest practices relating to the timing of vaccine testing by way of a Wall Street Journal article published in March. According to the article, Dormitzer alleged that, in order to affect the election results, Pfizer delayed its announcement of positive test results of the COVID vaccine. By slowing down the testing process, positive results were allegedly withheld from the public so that credit would be redirected from President Trump for the vaccine’s success.  

GSK alleges that in a meeting to discuss his relocation, Dormitzer requested that he be moved to Canada. Dormitzer, according to GSK officials, appeared fearful that the Trump administration would investigate him for his involvement in Pfizer’s development of the COVID-19 vaccine. After receiving this information, the committee reached out to GSK, which doubled down on its initial claims.

Reportedly, Dormitzer said that the timing of the vaccine was not a coincidence, and that “‘the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing’” to influence the outcome of the 2020 election. After compounding these claims with other evidence, the Judiciary Committee sent a letter to Dormitzer on March 15, requesting specific documentation pertaining to Pfizer’s COVID-19 vaccine work alongside a transcribed interview.

Dormitzer has since denied GSK’s allegations against him. Additionally, the scientist failed to comply with the committee’s request for documentation and an interview transcription.

His decision to deny their initial request prompted the committee to issue a subpoena on June 30 claiming that Dormitzer’s participation is key to the investigation.

According to the subpoena, Dormitzer’s attorney, Susan Brune, answered the committee’s initial request on May 29. Brune informed the committee that Dormitzer would not participate in an interview and failed to produce the requested documents. Any further information that the committee was seeking, Brune posited, could be gathered from Pfizer.

The committee has said it is unwilling to accept Dormitzer’s refusal to testify. In the letter included with the subpoena notice, Chairman Jim Jordan wrote, “Based off the information we have obtained to date, the Committee believes [Dormitzer’s] testimony is critical… the Committee’s request to Pfizer is separate and unique from the Committee’s request to [Dormtizer].”

Jordan went on to explain the severity of accusations against Dormitzer and other senior officials at Pfizer. Due to the potential impact of the alleged actions on the 2020 election, the accusations justify “substantial federal interest and [require] additional inquiry,” said Jordan, which could “in turn inform potential legislative reform.”

Despite Dormitzer and Pfizer CEO Albert Bourla’s claim that the timing of the COVID-19 vaccine testing and results were above board, the House Judiciary Committee presses on with its investigation. Now that he has been subpoenaed by the committee, Dormitzer can no longer dodge testifying before the committee in person. According to the subpoena, Dormitzer will appear for a deposition at 10 a.m. on July 22.